Flag of the European Union EU Clinical Trials Register Help

Clinical trials for eczema

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    341 result(s) found for: eczema. Displaying page 9 of 18.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2016-005025-37 Sponsor Protocol Number: RD.03.SPR.114322 Start Date*: 2017-08-30
    Sponsor Name:GALDERMA R&D, SNC
    Full Title: A randomized, double-blind, multi-center, parallel-group, placebo-controlled dose-ranging study to assess the efficacy and safety of nemolizumab (CD14152) in moderate-to-severe atopic dermatitis su...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10014184 Eczema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-003639-41 Sponsor Protocol Number: UP0089 Start Date*: 2020-11-06
    Sponsor Name:UCB Biopharma SRL
    Full Title: Phase 1/2A, randomized, placebo-controlled, single-ascending dose (Part A, participant- and investigator-blind) and repeated-dose (Part B, participant-, investigator-, and sponsor-blind) study to i...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) BG (Completed) DE (Completed) ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-000725-28 Sponsor Protocol Number: KY1005-CT05_(DRI17366) Start Date*: 2022-01-24
    Sponsor Name:Kymab Limited
    Full Title: A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe At...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) BG (Completed) HU (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2014-005518-44 Sponsor Protocol Number: 15-01/GentaBet-C Start Date*: 2015-10-27
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Cream (Test) vs. Diprogenta(R) Cream (Reference) vs. Vehicle in patients with bacterial ...
    Medical condition: Bacterial infected eczemas
    Disease: Version SOC Term Classification Code Term Level
    18.1 10021881 - Infections and infestations 10014199 Eczema infected PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-005519-18 Sponsor Protocol Number: 15-02/GentaBet-S Start Date*: 2015-12-14
    Sponsor Name:Dermapharm AG
    Full Title: Double-blind, randomised clinical study comparing efficacy and safety of Gentamicin 0.1%_Betamethasone 0.05% Ointment (Test) vs. Diprogenta(R) Ointment (Reference) vs. Vehicle in patients with bact...
    Medical condition: Bacterial infected eczemas
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10014199 Eczema infected PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002013-29 Sponsor Protocol Number: TREAT Start Date*: 2016-01-16
    Sponsor Name:Kings College London [...]
    1. Kings College London
    2. Guy's and St Thomas' NHS Foundation Trust
    Full Title: A Randomised Controlled Trial Assessing the Effectiveness, Safety and Cost-effectiveness of Methotrexate versus Ciclosporin in the Treatment of Severe Atopic Eczema in Children: The TREatment of Se...
    Medical condition: severe atopic ezcema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003641 Atopic eczema LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000376-26 Sponsor Protocol Number: ZPL521/101 Start Date*: 2016-05-09
    Sponsor Name:Ziarco Pharma Ltd
    Full Title: A Randomised, Adaptive Design, Double-Blind (3rd Party Open), Placebo Controlled, Sequential Group Study to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Applica...
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004899-30 Sponsor Protocol Number: 111187 Start Date*: 2016-12-21
    Sponsor Name:GlaxoSmithKline Research & Development Ltd.
    Full Title: Multi-center, Randomised, Double-blind, Parallel, Placebo Controlled Study Of 0.05% Clobetasone Butyrate Cream in Subjects with Eczema to evaluate the Efficacy and Safety.
    Medical condition: Eczema
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-003977-23 Sponsor Protocol Number: C3941002 Start Date*: 2021-03-19
    Sponsor Name:Pfizer Inc.
    Full Title: A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 6 WEEKS IN PARTICIPANTS ...
    Medical condition: Mild to moderate atopic dermatitis or mild to moderate plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002932-10 Sponsor Protocol Number: DRM06-AD04 Start Date*: 2020-03-06
    Sponsor Name:Dermira, a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) PL (Completed) EE (Completed) FR (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2018-000349-38 Sponsor Protocol Number: I4V-MC-JAIP Start Date*: 2019-04-15
    Sponsor Name:Eli Lilly and Company
    Full Title: I4V-MC-JAIP A Phase 3, Multicenter, Randomized, Double blind, Placebo controlled, Parallel group, Outpatient Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Baricitinib in Pediatric ...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Ongoing) FR (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-000448-23 Sponsor Protocol Number: RD.06.SPR.118126 Start Date*: 2022-04-05
    Sponsor Name:Galderma S.A.
    Full Title: A Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (aged 2 to 11 years) with Moderate-to-Sever...
    Medical condition: Moderate-to-Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) HU (Trial now transitioned) PL (Trial now transitioned) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001043-31 Sponsor Protocol Number: C3291037 Start Date*: 2019-03-20
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3B/4, MULTICENTER, RANDOMIZED, ASSESSOR BLINDED, VEHICLE AND ACTIVE (TOPICAL CORTICOSTEROID AND CALCINEURIN INHIBITOR) CONTROLLED, PARALLEL GROUP STUDY OF THE EFFICACY, SAFETY, AND LOCAL TO...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) BE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002166-40 Sponsor Protocol Number: RD.06.SPR.201591 Start Date*: 2021-11-18
    Sponsor Name:Galderma S.A.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis with Inadequate Response to or for Whom C...
    Medical condition: Moderate-to-Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Completed) LV (Completed) ES (Ongoing) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001561-32 Sponsor Protocol Number: 201900237 Start Date*: 2020-04-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Dupilumab in adults with severe chronic hand eczema with an inadequate response or intolerance to alitretinoin: a randomized, double-blind, placebo-controlled proof of concept efficacy study
    Medical condition: Hand eczema
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10066695 Chronic hand dermatitis LLT
    20.0 100000004858 10036145 Pompholyx eczema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001142-10 Sponsor Protocol Number: MOR106-CL-201 Start Date*: 2018-04-26
    Sponsor Name:Galapagos N.V.
    Full Title: A Phase II, randomized, double-blind, placebo-controlled repeated-dose study to evaluate the efficacy, safety, tolerability, and PK/PD of intravenously administered MOR106 in adult subjects with mo...
    Medical condition: atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-000955-28 Sponsor Protocol Number: R668-AD-1539 Start Date*: 2018-05-23
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A phase 2/3 study investigating the pharmacokinetics, safety, and efficacy of Dupilumab in patients aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis
    Medical condition: Part B: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003899-12 Sponsor Protocol Number: 271-12-205 Start Date*: 2014-10-22
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Protocol 271-12-205: A Phase 2 Multi-center, Randomized, Double-blind, Vehicle-controlled, Three-arm, Parallel Group Study to Assess the Safety, Tolerability, and Efficacy of Topical OPA-15406 Oint...
    Medical condition: Mild/Moderate Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10040785 Skin and subcutaneous tissue disorders SOC
    17.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    17.1 10040785 - Skin and subcutaneous tissue disorders 10014982 Epidermal and dermal conditions HLGT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2020-000314-15 Sponsor Protocol Number: LPS15991 Start Date*: 2021-08-17
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: Open label exploratory study to evaluate the effect of dupilumab on skin barrier function in patients with moderate to severe atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 20:20:01 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA